A flame-retardant microcapsule with a shell containing a cyclic phosphazene molecule, a process for forming a flame-retardant microcapsule with a shell containing a cyclic phosphazene molecule, and an article of manufacture including a flame-retardant microcapsule with a shell containing a cyclic phosphazene molecule are disclosed. The process for forming the flame-retardant microcapsule with the shell containing the cyclic phosphazene molecule may include providing a cyclic phosphazene molecule, forming an aqueous mixture containing the cyclic phosphazene molecule, adding a payload agent into the aqueous mixture, and adding a curing agent into the aqueous mixture.

A process a process of forming a non-halogenated flame retardant (FR) hindered amine light stabilizer (HALS) cross-linker is disclosed. The process includes forming a mixture that includes a first molecule having a hindered amine group. The first molecule corresponds to a functionalized 2,2,6,6-tetramethylpiperidine (TMP) molecule. The process also includes forming the non-halogenated FR HALS cross-linker via a chemical reaction of the first molecule a second molecule. The second molecule includes a phosphoryl group, a chloride group, and at least one cross-linkable (CL) moiety.

The invention provides a microRNA inhibitor that has two or more sequences complementary to the sequence of microRNA to be the target of inhibition, which two or more complementary sequences are linked via one or more linker residues.

A flame-retardant microcapsule with a shell containing a cyclic phosphazene molecule, a process for forming a flame-retardant microcapsule with a shell containing a cyclic phosphazene molecule, and an article of manufacture including a flame-retardant microcapsule with a shell containing a cyclic phosphazene molecule are disclosed. The process for forming the flame-retardant microcapsule with the shell containing the cyclic phosphazene molecule may include providing a cyclic phosphazene molecule, forming an aqueous mixture containing the cyclic phosphazene molecule, adding a payload agent into the aqueous mixture, and adding a curing agent into the aqueous mixture.

The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Disclosed is a method for the preparation of intermediates useful in the synthesis of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. Also disclosed is a method of preparing gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate.

The invention relates to a solid, particulate, urea-based blend composition comprising a urea-based compound in particulate form, one or more components in particulate form, selected from the group of nitrates, phosphates, sulphates and chlorides, and a urease inhibitor of the type phosphoric triamide, in particular N-(n-butyl) thiophosphoric triamide (nBTPT), wherein the urea-based blend composition is further characterized in that it comprises one or more reactive alkaline or alkaline-forming inorganic or organic compounds. The composition according to the invention has been stabilized against the degradation of a urease inhibitor of the type phosphoric triamide, in particular N-(n-butyl) thiophosphoric triamide (nBTPT). The invention further relates to a method for the manufacture of the claimed solid, particulate, urea-based blend composition.

Provided herein is a use of a high-boiling solvent in a mixture comprising a (thio)phosphoric acid derivative and a process including the addition of a high-boiling solvent to a mixture comprising a (thio)phosphoric acid derivative to recover the (thio)phosphoric acid from the mixture by an evaporation process.

The present disclosure involves a composition enriched in compound 61501b, wherein the compound 61501b has a purity of not less than 90% or more. The composition has a significant advantage in preparing a high-purity compound Sp-1. In addition, the present disclosure also provides a preparation method of the composition enriched in compound 61501b. The method adopts a crystallization technique to perform separation and purification, has a simple and convenient operation and good reproducibility, and therefore the compound 61501b in the prepared composition has high purity and quality. Further, the present disclosure also involves a novel crystal form of compound 61501b.

Provided is an organic silicon compound represented by the following general formula (1) ##STR00001##
(wherein R.sup.1 represents either an alkyl group that has 1 to 20 carbon atoms and may have a substituted group or a cycloalkyl group that has 3 to 20 carbon atoms and may have a substituted group; R.sup.2 represents either a hydrogen atom or a monovalent hydrocarbon group that has 1 to 20 carbon atoms and may have a substituted group, and R.sup.2 may be either identical or different; and each a independently represents an integer of 1 to 3). The novel silicon-containing compound of the present invention provides a cured product of a room temperature-curable organopolysiloxane composition that is particularly superior in fast curability.